Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized . . . Scheltens P, Atri A, Feldman H, Hansson O, Knop F, Sano M, Dethlefsen C, Johannsen P, León T, Hansen CT, Cummings J Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer's Disease (P11-9 013)
ALZFORUM | NETWORKING FOR A CURE Targeting T Cells for AD: Bar Them From Brain, Boost Them in Blood? At the AD PD meeting, scientists reported that in a mouse model of tauopathy, brain infiltration of IFN-γ-producing CD4+ Th1 cells worsened neurodegeneration Barring these cells from the brain with anti-CXCR3 antibodies provided neuroprotection Another approach—PD-L1 blockade—riles up these same T cells in the periphery
New NLRP3 Inhibitor Acts In Brain to Melt Obesity | ALZFORUM NLRP3 inhibitor must pass into brain to effect weight loss in obese mice The inhibitor calms microgliosis in the hypothalamus, raising hopes for such effects in other brain areas TN-783 complemented semaglutide, promoting further weight loss after the GLP-1 mimetic had plateaued
Novel LC-MS MS analysis of the GLP-1 analog semaglutide with its . . . Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T, Kim TH, Shin BS, Shin S Novel LC-MS MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats J Chromatogr B Analyt Technol Biomed Life Sci 2023 Apr 15;1221:123688 Epub 2023 Mar 22 PubMed
Therapeutics - ALZFORUM AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total